Anagrelide (hydrochloride)|cas 58579-51-4|DC Chemicals

Anagrelide (hydrochloride)|cas 58579-51-4|DC Chemicals

Anagrelide Hydrochloride(BL4162A) is a drug used for the treatment of essential thrombocytosis.

Target: PDE

Anagrelide hydrochloride is an oral imidazoquinazoline agent that has been shown to reduce elevated platelet counts and the risk of thrombosis in patients with thrombocythaemia in various myeloproliferative disorders (MPD).

Product Name: Anagrelide (hydrochloride)|Cat No: DC9580|Cas: 58579-51-4|Molecule Formular: C10H8Cl3N3O|Molecule Weight: 292.549|Other names: Anagrelide (hydrochloride)

Anagrelide Hydrochloride(BL4162A) is a drug used for the treatment of essential thrombocytosis.
Anagrelide hydrochloride is an oral imidazoquinazoline agent that has been shown to reduce elevated platelet counts and the risk of thrombosis in patients with thrombocythaemia in various myeloproliferative disorders (MPD). It is currently approved by the FDA as oral treatment for essential thrombocythaemia (ET) and thrombocythaemia associated with polycythaemia vera (PV). Anagrelide is known to inhibit platelet cyclic adenosine monophosphate (cAMP) phosphodiesterase at concentrations that exceed those achieved at doses used to treat ET. Anagrelide is extensively metabolised in the liver and its metabolites are primarily excreted in the urine. Anagrelide is an established platelet-reducing drug. Studies have also investigated the effects of anagrelide on platelets, indicating that platelet function is as important as platelet counts in ET.

For research only, not for human use!